Skip to main content
China Resources Pharmaceutical Group Limited logo

China Resources Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 3320 ISIN · HK0000311099 LEI · 3003004H1KDKMJ8JD874 HKEX Manufacturing
Open in API
Filings indexed 813 across all filing types
Latest filing 2024-10-30 Regulatory Filings
Country HK Hong Kong
Listing HKEX 3320

About China Resources Pharmaceutical Group Limited

http://www.crpharm.com

China Resources Pharmaceutical Group Limited operates an integrated pharmaceutical value chain encompassing research and development, manufacturing, distribution, and retail of medicines and healthcare products. As an investment holding company, it manages a diverse portfolio focused primarily on the domestic market. Its manufacturing capabilities span multiple therapeutic areas, including chemical drugs, biological drugs, natural medicine, and traditional Chinese medicine. The group leverages its extensive distribution network and retail operations to ensure broad market coverage across China.

Recent filings

Filing Released Lang Actions
ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF DONG-E-E-JIAO FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024
Regulatory Filings Classification · 95% confidence The document is an announcement of unaudited financial results for the nine months ended 30 September 2024 of Dong-E-E-Jiao, a subsidiary of China Resources Pharmaceutical Group Limited. It provides key financial figures but explicitly states that the financials are unaudited and that the full quarterly report is published on the Shenzhen Stock Exchange website. The document length is 3731 characters, which is relatively short and mainly serves to announce the availability of the quarterly report rather than presenting a full interim or quarterly report itself. According to the 'Menu vs Meal' rule, such announcements that refer to a report being published elsewhere and are short in length should be classified as Regulatory Filings (RNS) rather than as an Interim/Quarterly Report (IR). Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-10-30 English
ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF CR SANJIU FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024
Report Publication Announcement Classification · 95% confidence The document is an announcement of unaudited financial results for the nine months ended 30 September 2024 for CR Sanjiu, a subsidiary of China Resources Pharmaceutical Group Limited. It provides key financial data but explicitly states that the full quarterly report is published on the Shenzhen Stock Exchange website and that this announcement is a summary. The document length is 3480 characters, which is relatively short and mainly serves to inform about the release of the quarterly report rather than containing the full report itself. According to the 'Menu vs Meal' rule, such a document is a report publication announcement rather than the full interim/quarterly report. Therefore, the appropriate classification is Report Publication Announcement (RPA).
2024-10-25 English
ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF JIANGZHONG PHARMACEUTICAL FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024
Earnings Release Classification · 95% confidence The document is an announcement of unaudited financial results for Jiangzhong Pharmaceutical for the nine months ended 30 September 2024. It includes key financial figures but explicitly states the financials are unaudited and prepared according to PRC GAAP. The document is relatively short (3874 characters) and refers readers to the full quarterly report published on the Shanghai Stock Exchange website. The text is an announcement summarizing financial results rather than a full interim or quarterly report containing detailed financial statements and analysis. Therefore, it fits best as an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results with key highlights only. 9M 2024
2024-10-25 English
ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF KPC FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024
Regulatory Filings Classification · 95% confidence The document is an announcement of unaudited financial results for the nine months ended 30 September 2024 for KPC Pharmaceuticals, a subsidiary of China Resources Pharmaceutical Group Limited. It provides key financial figures such as revenue, net profit, cash flow, total assets, liabilities, and owner's equity. The document explicitly states that these are unaudited financials and refers readers to the full quarterly report published on the Shanghai Stock Exchange website. The document length is 3473 characters, which is relatively short and primarily serves as a summary announcement rather than a full financial report. It does not contain detailed financial statements or substantive financial analysis itself, but rather points to the full quarterly report elsewhere. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is an announcement of financial results without the full report content, and it is under the 5,000 character threshold. It is not a full Interim/Quarterly Report (IR) because it lacks comprehensive financial data and analysis within the text itself.
2024-10-25 English
ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF CR DOUBLE-CRANE FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024
Earnings Release Classification · 95% confidence The document is an announcement of unaudited financial results for the nine months ended 30 September 2024 for CR Double-Crane, a subsidiary of China Resources Pharmaceutical Group Limited. It provides key financial figures such as revenue, net profit, cash flow, total assets, liabilities, and owner's equity. The document explicitly states that the financials are unaudited and prepared according to PRC GAAP, and it advises shareholders to exercise caution. The document is relatively short (3622 characters) and refers readers to the full quarterly report published on the Shanghai Stock Exchange website. This indicates that the document is an initial announcement of quarterly financial results rather than the full interim report itself. According to the rules, initial announcements of quarterly/periodical financial results with key highlights only are classified as Earnings Release (ER). 9M 2024
2024-10-25 English
ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF CR BOYA BIO-PHARMACEUTICAL FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024
Regulatory Filings Classification · 95% confidence The document is an announcement of unaudited financial results for the nine months ended 30 September 2024 for CR Boya Bio-pharmaceutical. It includes key financial figures but explicitly states the financials are unaudited and limited to the subsidiary only. The document is relatively short (3788 characters) and primarily serves to inform about the release of the quarterly report rather than presenting a full comprehensive financial report itself. It also directs readers to the Shenzhen Stock Exchange website for the full quarterly report. This fits the pattern of an Interim / Quarterly Report announcement but given the short length and the nature of the document as an announcement rather than the full report, it aligns best with Regulatory Filings (RNS) as a general regulatory announcement about financial results. It is not a full Interim Report (IR) because it lacks substantive financial data and analysis beyond summary figures and is not the full report itself. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2024-10-24 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.